|
|
Vaccine Detail
|
Melacine |
| Vaccine Information |
- Vaccine Name: Melacine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007640
- Type: Allogenic cell
- Status: Research
- Antigen: class I antigens A2 and/or HLA-C3
- Immunization Route: Intramuscular injection (i.m.)
- Description: Phase I and II trials in stage IV melanoma showed low-level antitumor activity, but this vaccine has its greatest promise in the adjuvant setting. A phase III trial indicated a survival benefit for Melacine in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3 (Sondak and Sosman, 2003).
|
| Host Response |
|
|
| References |
Sondak and Sosman, 2003: Sondak VK, Sosman JA. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Seminars in cancer biology. 2003; 13(6); 409-415. [PubMed: 15001159].
|
|
